The US Food and Drug Administration (FDA) has granted approval to and ‘s Epkinly (epcoritamab-bysp) to (DLBCL) in adult patients.
Epkinly has been approved as the first and only T-cell-engaging bispecific antibody to treat adults with DLBCL not otherwise specified (NOS), including DLBCL arising from indolent lymphoma and high-grade B鈥揷ell lymphoma (HGBL), following two or more lines of systemic therapies.
The regulator granted approval under its accelerated approval programme based on the durability of the response and the response rate of the therapy.
Continued approval for the indication is dependent on verification and description of the clinical benefit of Epkinly in confirmatory trials.
research and development senior vice-president and chief scientific officer Thomas Hudson stated: 鈥淒LBCL is an aggressive cancer type that can rapidly progress and resist treatment.
鈥淭he FDA approval of Epkinly represents a new treatment mechanism of action for third-line DLBCL patients.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData鈥淎s a non-chemotherapy, single-agent treatment for DLBCL patients, we hope that Epkinly can effectively treat this aggressive cancer type and can be used for patient care quickly and in an off-the-shelf form for physicians.
鈥淭he approval is just the first step, with our partner , towards a shared goal of developing a core therapy for patients with B-cell malignancies.鈥�
The approval from the FDA was supported by data obtained from the Phase I/II EPCORE NHL-1 clinical trial.
Treatment with Epkinly delivered a 61% overall response rate, a 38% complete response rate and 15.6 months of median duration of response to the therapy in heavily pre-treated R/R DLBCL patients.
Pyrexia, diarrhoea, nausea, fatigue, abdominal pain, CRS, musculoskeletal pain and injection site reactions were the most common adverse reactions observed.
